About Celularity
Celularity (NASDAQ:CELU) is a biotechnology company focused on developing cellular therapies for cancer, infectious diseases, and degenerative diseases. The company harnesses the power of cells, particularly placental-derived cells, to create innovative medical treatments. Celularity is at the forefront of research and development in regenerative medicine, aiming to unlock new therapeutic pathways and improve outcomes for patients facing serious health conditions. Their projects span across various phases of clinical trials, demonstrating their commitment to advancing healthcare through cutting-edge science. Celularity's objectives include accelerating the availability of transformative treatments that can significantly enhance patient care and quality of life, while also exploring the vast potential of cellular medicine to address unmet medical needs.
Snapshot
Operations
Products and/or services of Celularity
- CYNK-001 is an investigational, off-the-shelf, allogeneic therapy utilizing natural killer (NK) cells from placental hematopoietic stem cells for cancer and infectious diseases.
- APL-1 is a placental-derived adherent stromal cell therapy aimed at treating acute respiratory distress syndrome, including that caused by COVID-19.
- BIOVANCE is a decellularized, dehydrated human amniotic membrane used for wound care and surgical applications, promoting natural healing processes.
- Interfyl is a connective tissue matrix product designed for surgical procedures, supporting soft tissue repair and regeneration.
- UltraMIST system delivers low-frequency ultrasound to wounds, aiding in pain reduction, wound healing, and tissue regeneration.
- PDA-002, an allogeneic, placenta-derived, adherent stromal cell therapy, targets improving peripheral artery disease outcomes by promoting angiogenesis.
Celularity executive team
- Dr. Robert Joseph Hariri M.D., Ph.D.Founder, CEO & Chairman
- Mr. John R. HainesSenior EVP, Corporate Secretary, Global Manager & Chief Administrative Officer
- Mr. Joseph C. DosSantos CPA, MBASenior VP of Finance & Interim CFO
- Mr. Carlos RamirezSVP of Investor Relations
- Dr. Stephen A. Brigido D.P.M.President of Degenerative Diseases
- Sharmila Koppisetti M.D.Senior Vice President of Clinical Dev. Immunology & Drug Safety
- Mr. Tim WilkSenior Vice President of Technical Operations
- Mr. David Jakob Lemus CPA, M.S., MBATreasurer